Company · founded 2013
Ampel BioSolutions (United States)
Charlottesville, United States · ampelbiosolutions.com
- Citations, last 5 years
- 630
- Works, last 5 years
- 91
- h-index
- 56
- Scientists listed
- 11
- Grants since 2016
- 18
Grants received
2021–2022 · research · R41
Furopyrimidines as novel inhibitors of henipaviruses
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2021–2023 · research · R41
Furopyrimidines as novel inhibitors of henipaviruses
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2021–2025 · research · R42
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2021–2026 · research · R42
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2021–2025 · research · R42
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2021–2022 · research · R42
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2019–2022 · research · R41
Development of group 2 influenza A virus entry inhibitors
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2019–2021 · research · R41
Development of group 2 influenza A virus entry inhibitors
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Inexpensive, sensitive and specific, point-of-care diagnostic for bacterial infections in the central nervous system
Theresa N Schein · Ampel BioSolutions (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Inexpensive, sensitive and specific, point-of-care diagnostic for bacterial infections in the central nervous system
Theresa N Schein · Ampel BioSolutions (United States) · funded by National Institutes of Health
2016–2024 · research · R42
4-(Aminomethyl) benzamides as novel anti-Ebola agents
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2016–2018 · research · R41
4-(Aminomethyl) benzamides as novel anti-Ebola agents
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2016–2018 · research · R41
4-Aminopiperidines as novel anti-influenza agents
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2016–2022 · research · R42
4-(Aminomethyl) benzamides as novel anti-Ebola agents
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Furopyrroles as Novel anti-Ebola Agents
Norton P. Peet · Ampel BioSolutions (United States) · funded by Centers for Disease Control and Prevention
2016–2019 · research · R41
4-Aminopiperidines as novel anti-influenza agents
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2016–2022 · research · R42
4-(Aminomethyl) benzamides as novel anti-Ebola agents
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health
2016–2019 · research · R41
4-(Aminomethyl) benzamides as novel anti-Ebola agents
Lijun Rong · Ampel BioSolutions (United States) · funded by National Institutes of Health